Newsletter: February 2022 - Multidisciplinary Association for Psychedelic Studies

atai Impact Donates to MAPS to Support Pioneering Work in Psychedelic Medicine

February 25, 2022

Dear friends and supporters,

We’re excited to share that atai Life Sciences’ philanthropic arm, atai Impact, gave a $500,000 donation to MAPS on February 16! This donation demonstrates the collaboration between leading non-profit and commercial organizations to advance psychedelic medicine to find treatments and therapies for mental health. Watch the video about this donation on our Instagram page.

“We were already facing a global mental health crisis, but the pandemic has escalated this even further. To solve this crisis requires innovation, passion, and collaboration. MAPS has been the driving force of the psychedelic renaissance over the last 35 years, promoting healing and well-being through education and research into psychedelics and their potential to revolutionize mental health for those in need. Their work has been an incredible source of inspiration and motivation to all of us at atai, and we’re pleased to work alongside them,” said Florian Brand, CEO and co-founder of atai Life Sciences. Click here to read our full statement.

MAPS Celebrates Black History Month

We are celebrating Black History Month this February by reflecting on the many contributions the Black community has made to the fields of psychedelic science, medicine, and therapy. Visit our webpage to see a limited, intimate list of visionary Black leaders and educational resources pertaining to justice, race, and equity in psychedelics. Learn about the groundbreaking work of Sara Reed, M.S., Dr. Carl Hart, Jamilah R. George, M.Div., Monnica Williams, Ph.D., Camille Barton, and Ayize Jama-Everett. While we acknowledge we have a long way to go, we commit working towards collective liberation.

Phase 3 Trials of MDMA-Assisted Therapy for PTSD: Study Site Opens for Phone Screening in Tel Hashomer, Israel
On February 3, our Phase 3 study site for MDMA-assisted psychotherapy for PTSD in Tel Hashomer, Israel, officially opened for phone screenings and informed consent visits. Led by Principal Investigator Jana Yakirevitch, M.D., this is an FDA-regulated Phase 3 clinical trial of MDMA-assisted psychotherapy for PTSD.

First Participant Treated in A Phase 2, Open-Label, Randomized Comparative Effectiveness Study for MDMA-Assisted Therapy in U.S. Military Veterans with Chronic PTSD
On February 3, 2022, the first participant was treated in the MAPS-sponsored Phase 2, open-label study of the comparative effectiveness of two vs. three MDMA-assisted therapy sessions in Veterans with PTSD at the James J. Peters Veterans Affairs (VA) Medical Center in Bronx, New York. The study is expected to treat up to 60 participants over 2-3 years.

Win Prizes By Referring Talent To Make MDMA a Legal Medicine
Learn about the many roles available at MAPS, MAPS Public Benefit Corporation (MAPS PBC), and MAPS Europe — and share that information far and wide! If a successful candidate has noted that you referred them for a role, you’ll receive a MAPS Store gift set and will be entered to win a drawing for a Meet & Greet with Rick Doblin, Ph.D., or Amy Emerson, CEO of MAPS PBC! Do you know the perfect new Major Gifts Officer, Medical Monitor, or Director of Clinical Operations? Let them know about these exciting roles.

MDMA Therapy Training Program Releases Training Schedule
The 2022 training schedule for our MDMA Therapy Training Program is now available on our website. The schedule includes options for a blended training format (online and in-person) as well as an entirely virtual training format. Visit our website for more information.

Subscribe to the Psychedelic Science 2023 Email List
Join MAPS members, researchers, students, clinicians, advocates, patients, therapists, political leaders, and psychedelic enthusiasts from around the world at Psychedelic Science 2023, taking place next year from June 17-25! Be sure to sign up for exclusive email updates to receive news, schedules, and details about this revolutionary event.

Follow MAPS on Facebook, Twitter, Instagram, YouTube, and LinkedIn.

The MAPS Newsletter is emailed to subscriber inboxes and posted on our Newsletter webpage every month.